Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report)'s share price was up 6.5% on Thursday . The company traded as high as $1.79 and last traded at $1.79. Approximately 3,325,992 shares changed hands during trading, an increase of 21% from the average daily volume of 2,738,776 shares. The stock had previously closed at $1.68.
Analyst Ratings Changes
Several research analysts have recently issued reports on BMEA shares. Oppenheimer restated an "outperform" rating on shares of Biomea Fusion in a report on Tuesday, August 5th. D. Boral Capital restated a "buy" rating and set a $16.00 price objective on shares of Biomea Fusion in a report on Friday, October 3rd. Citigroup dropped their price objective on shares of Biomea Fusion from $9.00 to $7.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Weiss Ratings restated a "sell (e+)" rating on shares of Biomea Fusion in a report on Wednesday. Finally, Scotiabank dropped their price objective on shares of Biomea Fusion from $30.00 to $10.00 and set a "sector outperform" rating on the stock in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Biomea Fusion has an average rating of "Moderate Buy" and an average target price of $9.50.
Read Our Latest Report on Biomea Fusion
Biomea Fusion Price Performance
The firm has a market cap of $106.52 million, a P/E ratio of -0.59 and a beta of -0.12. The stock's 50 day moving average is $1.88 and its two-hundred day moving average is $1.90.
Biomea Fusion (NASDAQ:BMEA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.08. As a group, research analysts forecast that Biomea Fusion, Inc. will post -3.93 EPS for the current fiscal year.
Institutional Trading of Biomea Fusion
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marex Group plc bought a new stake in Biomea Fusion in the second quarter valued at about $81,000. Engineers Gate Manager LP bought a new stake in Biomea Fusion during the second quarter worth about $26,000. Bridgeway Capital Management LLC grew its stake in Biomea Fusion by 99.2% during the second quarter. Bridgeway Capital Management LLC now owns 70,300 shares of the company's stock worth $127,000 after buying an additional 35,000 shares during the last quarter. Aisling Capital Management LP grew its stake in Biomea Fusion by 156.5% during the second quarter. Aisling Capital Management LP now owns 2,048,757 shares of the company's stock worth $3,688,000 after buying an additional 1,250,000 shares during the last quarter. Finally, Scotia Capital Inc. bought a new stake in Biomea Fusion during the second quarter worth about $459,000. Institutional investors own 96.72% of the company's stock.
About Biomea Fusion
(
Get Free Report)
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biomea Fusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biomea Fusion wasn't on the list.
While Biomea Fusion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
